Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
| Cat.No. | Product Name | Price |
|---|---|---|
| CSC-DC001819 | Panoply™ Human C19ORF10 Knockdown Stable Cell Line | Inquiry |
| CSC-DC007584 | Panoply™ Human IL27 Knockdown Stable Cell Line | Inquiry |
| CSC-SC001819 | Panoply™ Human C19ORF10 Over-expressing Stable Cell Line | Inquiry |
| CSC-SC007584 | Panoply™ Human IL27 Over-expressing Stable Cell Line | Inquiry |
| Cat.No. | Product Name | Price |
|---|---|---|
| AD02298Z | Human C19orf10 adenoviral particles | Inquiry |
| AD08049Z | Human IL27 adenoviral particles | Inquiry |
| LV06868L | human C19orf10 (NM_019107) lentivirus particles | Inquiry |
| LV15411L | human IL27 (NM_145659) lentivirus particles | Inquiry |
| Cat.No. | Product Name | Price |
|---|---|---|
| SHH250082 | shRNA set against Human C19orf10 (NM_019107.3) | Inquiry |
| SHH318801 | shRNA set against Human IL27 (NM_145659.3) | Inquiry |
| SHH318805 | shRNA set against Mouse IL27 (NM_145636.1) | Inquiry |
| SHL172590 | shRNA set against Mouse Il27(NM_145636.1) | Inquiry |
| SHL172990 | shRNA set against Human IL27(NM_145659.3) | Inquiry |
| Cat.No. | Product Name | Price |
|---|---|---|
| CDFG002289 | Human C19orf10 cDNA Clone(NM_019107.3) | Inquiry |
| CDFG009054 | Human IL27 cDNA Clone(NM_145659.3) | Inquiry |
| CDFL006172 | Mouse Il27 cDNA Clone(NM_145636.1) | Inquiry |
| MiUTR1H-01192 | C19ORF10 miRNA 3'UTR clone | Inquiry |
| MiUTR1H-04913 | IL27 miRNA 3'UTR clone | Inquiry |
| MiUTR1M-06007 | IL27 miRNA 3'UTR clone | Inquiry |
| CDCB156881 | Rat IL27 ORF clone (XM_344962.4) | Inquiry |
| CDCB159949 | Human C19ORF10 ORF clone (BC010129) | Inquiry |
| CDCB188264 | Rabbit IL27 ORF clone (XM_002711891.2) | Inquiry |
| CDCL184865 | Mouse IL27 ORF clone(NM_145636.1) | Inquiry |
| CDCR304665 | Human C19orf10 ORF Clone(NM_019107.3) | Inquiry |
| CDCS414956 | Human C19orf10 ORF Clone (BC010129) | Inquiry |
| CDCS418161 | Human C19ORF10 ORF Clone (BC062422) | Inquiry |
The IL-27 gene encodes a key subunit of the heterodimeric cytokine IL-27, which shares structural homology with interleukin-12A (IL-12A). IL-27 functions as a heterodimer composed of two subunits linked by a disulfide bond: p28 (IL-27A), encoded by IL-27, and EBI3, encoded by the Epstein-Barr virus-induced gene 3. This unique heterodimeric structure positions IL-27 distinctly within the cytokine family, structurally homologous to IL-12 and IL-23, yet functionally unique. IL-27 signaling is mediated through a type I cytokine receptor complex composed of WSX-1 (specific IL-27-binding subunit) and gp130 (a shared signaling subunit used by multiple cytokines), a configuration that enables complex cross-talk with other cytokine pathways.
IL-27 is a bifunctional immunoregulatory cytokine that can exert both pro-inflammatory effects to assist host defense and anti-inflammatory effects to maintain immune homeostasis and prevent excessive tissue damage. During the initiation of adaptive immunity, IL-27 collaborates with IL-12 to strongly induce IFN-γ production by naïve CD4+ T cells, promoting Th1 differentiation. This involves activation of intracellular signaling networks, including STAT1, STAT3, STAT4, and STAT5 phosphorylation, and upregulation of T-bet and IL-12 receptor β2, reinforcing Th1 lineage commitment.
Figure 1. A schematic model of IL-27 effect on superoxide generation. (Sowrirajan B, et al. 2017)
Conversely, IL-27 suppresses differentiation of Th17 cells and IL-17 production via STAT1-dependent mechanisms, providing protective effects in autoimmune conditions such as experimental autoimmune encephalomyelitis. IL-27 also inhibits Th2 differentiation and regulates induced regulatory T cell development through STAT1-independent pathways. Beyond CD4+ T cells, IL-27 enhances CD8+ T cell cytotoxicity, promotes B cell class-switch recombination, and modulates innate immune cell functions, including monocytes, macrophages, and dendritic cells. Additionally, IL-27 exhibits anti-tumor and anti-angiogenic activity, partly by inducing chemokines such as IP-10 and MIG, and demonstrates potential antiviral effects by inhibiting viral replication.
IL-27's dual immunomodulatory properties make it a promising target for therapeutic intervention in infectious diseases, autoimmune disorders, and cancer. In infections, its pro-inflammatory and Th1-promoting activity is critical for defense against intracellular pathogens, while defects may lead to persistent infections. Conversely, pathogens may exploit IL-27's anti-inflammatory effects to evade immunity.
In autoimmune diseases, IL-27's suppression of Th17 responses positions it as a potential therapeutic cytokine; exogenous IL-27 or enhanced signaling has shown efficacy in multiple animal models of autoimmunity. In cancer, IL-27's anti-angiogenic effects and ability to activate CD8+ T cells and NK cells support its role as an anti-tumor cytokine. However, therapeutic modulation is challenging due to the delicate balance between its pro- and anti-inflammatory functions: IL-27 agonists may inadvertently suppress beneficial Th17 or Treg responses, whereas antagonists could reduce essential anti-tumor or anti-infection immunity. Future research aims to elucidate IL-27's tissue- and disease-specific roles and optimize strategies for precise delivery, timing, or combination therapy to safely harness this multifunctional cytokine.
References